Psyence Biomedical Postpones Effective Date Of Its 1-For-6.25 Reverse Stock Split To Later Date

Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock.

As previously disclosed, the Company's Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026. Following further internal consideration, the Company has elected to delay the effectiveness of the reverse stock split to a later date.

The Company will issue a subsequent press release and file any required notifications with Nasdaq prior to establishing a new effective date for the reverse stock split. Until such time, the Company's common stock will continue to trade on the Nasdaq Capital Market on a split-unadjusted basis under the ticker symbol "PBM" and under its current CUSIP 74449F308.

The Board of Directors retains the discretion to determine if and when the reverse stock split will be effected.